Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 248

Cited In for PubMed (Select 20141835)


Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling.

Hirata E, Girotti MR, Viros A, Hooper S, Spencer-Dene B, Matsuda M, Larkin J, Marais R, Sahai E.

Cancer Cell. 2015 Apr 13;27(4):574-88. doi: 10.1016/j.ccell.2015.03.008.


The E3 ubiquitin ligase Trim7 mediates c-Jun/AP-1 activation by Ras signalling.

Chakraborty A, Diefenbacher ME, Mylona A, Kassel O, Behrens A.

Nat Commun. 2015 Apr 8;6:6782. doi: 10.1038/ncomms7782.


Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer.

Lindsay CR, Spiliopoulou P, Waterston A.

Ther Adv Med Oncol. 2015 Mar;7(2):107-21. doi: 10.1177/1758834014566619. Review.


Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.

Pagliarini R, Shao W, Sellers WR.

EMBO Rep. 2015 Mar;16(3):280-96. doi: 10.15252/embr.201439949. Epub 2015 Feb 13. Review.


Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.

Atefi M, Titz B, Avramis E, Ng C, Wong DJ, Lassen A, Cerniglia M, Escuin-Ordinas H, Foulad D, Comin-Anduix B, Graeber TG, Ribas A.

Mol Cancer. 2015 Feb 3;14(1):27. doi: 10.1186/s12943-015-0293-5.


Genotyping of cutaneous melanoma.

Glitza IC, Davies MA.

Chin Clin Oncol. 2014 Sep;3(3):27.


BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth.

Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis G, Gangadhar TC, Schuchter LM, Lieu M, Khare S, Halloran MB, Herlyn M, Kaufman RE.

Clin Cancer Res. 2015 Apr 1;21(7):1652-64. doi: 10.1158/1078-0432.CCR-14-1554. Epub 2015 Jan 23.


Update on Molecular Pathology of Cutaneous Melanocytic Lesions: What is New in Diagnosis and Molecular Testing for Treatment?

van Engen-van Grunsven AC, Kusters-Vandevelde H, Groenen PJ, Blokx WA.

Front Med (Lausanne). 2014 Oct 31;1:39. doi: 10.3389/fmed.2014.00039. eCollection 2014. Review.


Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer.

Kelleher FC, Solomon B, McArthur GA.

J Pers Med. 2012 Apr 10;2(2):35-49. doi: 10.3390/jpm2020035. Review.


Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R.

J Thorac Oncol. 2015 Jan;10(1 Suppl 1):S1-63. doi: 10.1097/JTO.0000000000000405.


Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders.

Schadt EE, Buchanan S, Brennand KJ, Merchant KM.

Front Pharmacol. 2014 Dec 2;5:252. doi: 10.3389/fphar.2014.00252. eCollection 2014. Review.


Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.

Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BM, Menard D, McLeary R, Johnson L, Fish L, Ejiama S, Sanchez-Laorden B, Hohloch J, Carragher N, Macleod K, Ashton G, Marusiak AA, Fusi A, Brognard J, Frame M, Lorigan P, Marais R, Springer C.

Cancer Cell. 2015 Jan 12;27(1):85-96. doi: 10.1016/j.ccell.2014.11.006. Epub 2014 Dec 11.


BRAF inhibitors: experience in thyroid cancer and general review of toxicity.

Cabanillas ME, Patel A, Danysh BP, Dadu R, Kopetz S, Falchook G.

Horm Cancer. 2015 Feb;6(1):21-36. doi: 10.1007/s12672-014-0207-9. Epub 2014 Dec 3.


Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.

Litvak AM, Paik PK, Woo KM, Sima CS, Hellmann MD, Arcila ME, Ladanyi M, Rudin CM, Kris MG, Riely GJ.

J Thorac Oncol. 2014 Nov;9(11):1669-74. doi: 10.1097/JTO.0000000000000344.


The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.

Wada M, Horinaka M, Yamazaki T, Katoh N, Sakai T.

PLoS One. 2014 Nov 25;9(11):e113217. doi: 10.1371/journal.pone.0113217. eCollection 2014.


Catalytic mechanisms and regulation of protein kinases.

Wang Z, Cole PA.

Methods Enzymol. 2014;548:1-21. doi: 10.1016/B978-0-12-397918-6.00001-X.


Cutaneous epithelial tumors induced by vemurafenib involve the MAPK and Pi3KCA pathways but not HPV nor HPyV viral infection.

Frouin E, Guillot B, Larrieux M, Tempier A, Boulle N, Foulongne V, Girard C, Costes V, Solassol J.

PLoS One. 2014 Oct 31;9(10):e110478. doi: 10.1371/journal.pone.0110478. eCollection 2014.


BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.

Yaktapour N, Meiss F, Mastroianni J, Zenz T, Andrlova H, Mathew NR, Claus R, Hutter B, Fröhling S, Brors B, Pfeifer D, Pantic M, Bartsch I, Spehl TS, Meyer PT, Duyster J, Zirlik K, Brummer T, Zeiser R.

J Clin Invest. 2014 Nov;124(11):5074-84. doi: 10.1172/JCI76539. Epub 2014 Oct 20.


Drugging the undruggable RAS: Mission possible?

Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ.

Nat Rev Drug Discov. 2014 Nov;13(11):828-51. doi: 10.1038/nrd4389. Epub 2014 Oct 17. Review.


Data-derived modeling characterizes plasticity of MAPK signaling in melanoma.

Bernardo-Faura M, Massen S, Falk CS, Brady NR, Eils R.

PLoS Comput Biol. 2014 Sep 4;10(9):e1003795. doi: 10.1371/journal.pcbi.1003795. eCollection 2014 Sep.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk